Clinical trial
A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
NCT07214376 is registered in ClinicalTrials.gov with Pulnovo Medical, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Placebo-procedure Controlled Trial of the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System PULmonary Artery Denervation Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease
- Lead sponsor
- Pulnovo Medical, Inc.
- Phase
- Not applicable
- Overall status
- Recruiting
- Start date
- August 21, 2026
- Completion date
- December 31, 2031
- Enrollment
- 750 (estimated)
- Sites
- 16
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, heart failure, heart failure with mid range ejection fraction, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, hypertension, pulmonary hypertension, vascular diseases